Skip to Content


Oral Dosage Form New Animal Drugs; Neomycin Sulfate Oral Solution

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 53581


Food and Drug Administration, HHS.


Final rule.


The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Med-Pharmex, Inc. The ANADA provides for the oral use of neomycin sulfate solution for the treatment and control of colibacillosis in cattle, swine, sheep, and goats.


This rule is effective September 5, 2000.

Start Further Info


Dianne T. McRae, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0212.

End Further Info End Preamble Start Supplemental Information


Med-Pharmex, Inc., 2727 Thompson Creek Rd., Pomona, CA 91767-1861, filed ANADA 200-289 that provides for the oral use of neomycin sulfate solution for the treatment and control of colibacillosis in cattle, swine, sheep, and goats. Med-Pharmex's ANADA 200-289 NEORAL® (neomycin sulfate) Oral Solution is approved as a generic copy of Pharmacia & Upjohn's NADA 011-315 NEOMIX® 325 Soluble Powder. The application is approved as of July 3, 2000, and the regulations in 21 CFR 520.1485 are amended to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects in 21 CFR Part 520

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part


End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
Start Amendment Part

2. Section 520.1485

End Amendment Part Start Signature

Dated: August 23, 2000.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 00-22571 Filed 9-1-00; 8:45 am]